BIOVENTIX PLC

Director's Dealing • Nov 22, 2024

National Storage Mechanism | Additional information

RNS Number : 3923N

BioVentix PLC

22 November 2024

Bioventix plc  

("Bioventix" or "the Company")  

Director Dealing  

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 22 November 2024 that on 22 November 2024 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 24 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at an average price of 3,822 pence per Ordinary Share (the "Purchase"). The Ordinary Shares were purchased under a dividend reinvestment plan ("DRIP").  

Following the Purchase, Bruce Hiscock has a beneficial interest in 1,113 Ordinary Shares, representing approximately 0.02 per cent. of the issued share capital of the Company.  

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.  

For further information please contact:  

Bioventix plc   Peter Harrison	Chief Executive Officer	Tel: 01252 728 001
Cavendish   Geoff Nash / Abigail Kelly Nigel Birks / Harriet Ward	Corporate Finance   ECM	Tel: 020 7220 0500

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them  

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bruce Hiscock
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Bioventix Plc
b)	LEI	213800225MHX7LZQY108
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary Shares of 5 pence each
Identification code	GB00B4QVDF07
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	24 Ordinary Shares   3,822 pence
d)	Aggregated information:   ·     Aggregated volume   ·     Price	Purchase of 24 Ordinary Shares at 3,855 pence each
e)	Date of the transaction	22 November 2024
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEASFAASLLFFA